nach oben

Nuclear Medicine and Molecular Imaging

Erschienen in:

18.02.2019 | Review

Quantitative Imaging of Alpha-Emitting Therapeutic Radiopharmaceuticals

verfasst von: Youngho Seo

Erschienen in: Nuclear Medicine and Molecular Imaging | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Targeted alpha therapy (TAT) is an active area of drug development as a highly specific and highly potent therapeutic modality that can be applied to many types of late-stage cancers. In order to properly evaluate its safety and efficacy, understanding biokinetics of alpha-emitting radiopharmaceuticals is essential. Quantitative imaging of alpha-emitting radiopharmaceuticals is often possible via imaging of gammas and positrons produced during complex decay chains of these radionuclides. Analysis of the complex decay chains for alpha-emitting radionuclides (Tb-149, At-211, Bi-212 (decayed from Pb-212), Bi-213, Ra-223, Ac-225, and Th-227) with relevance to imageable signals is attempted in this mini-review article. Gamma camera imaging, single-photon emission computed tomography, positron emission tomography, bremsstrahlung radiation imaging, Cerenkov luminescence imaging, and Compton cameras are briefly discussed as modalities for imaging alpha-emitting radiopharmaceuticals.

Elgqvist J, Frost S, Pouget JP, Albertsson P. The potential and hurdles of targeted alpha therapy - clinical trials and beyond. Front Oncol. 2014;3:324.CrossRefPubMedPubMedCentral

Nurdan TC, Nurdan K, Brill AB, Walenta AH. Design criteria for a high energy Compton camera and possible application to targeted cancer therapy. J Instrum. 2015;10.

Beyer GJ, Miederer M, Vranjes-Duric S, Comor JJ, Kunzi G, Hartley O, et al. Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using 149Tb-rituximab. Eur J Nucl Med Mol Imaging. 2004;31:547–54.CrossRefPubMed

Lassmann M, Eberlein U. Targeted alpha-particle therapy: imaging, dosimetry, and radiation protection. Ann ICRP. 2018;47:187–95.CrossRefPubMed

Robertson AKH, Ramogida CF, Rodriguez-Rodriguez C, Blinder S, Kunz P, Sossi V, et al. Multi-isotope SPECT imaging of the (225)Ac decay chain: feasibility studies. Phys Med Biol. 2017;62:4406–20.CrossRefPubMed

Hamacher KA, Den RB, Den EI, Sgouros G. Cellular dose conversion factors for alpha-particle--emitting radionuclides of interest in radionuclide therapy. J Nucl Med. 2001;42:1216–21.PubMed

Sofou S, Thomas JL, Lin HY, McDevitt MR, Scheinberg DA, Sgouros G. Engineered liposomes for potential alpha-particle therapy of metastatic cancer. J Nucl Med. 2004;45:253–60.PubMed

Jonasdottir TJ, Fisher DR, Borrebaek J, Bruland OS, Larsen RH. First in vivo evaluation of liposome-encapsulated 223Ra as a potential alpha-particle-emitting cancer therapeutic agent. Anticancer Res. 2006;26:2841–8.PubMed

Woodward J, Kennel SJ, Stuckey A, Osborne D, Wall J, Rondinone AJ, et al. LaPO4 nanoparticles doped with actinium-225 that partially sequester daughter radionuclides. Bioconjug Chem. 2011;22:766–76.CrossRefPubMed

10.

Sgouros G, Ballangrud AM, Jurcic JG, McDevitt MR, Humm JL, Erdi YE, et al. Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med. 1999;40:1935–46.PubMed

11.

Miederer M, McDevitt MR, Sgouros G, Kramer K, Cheung NK, Scheinberg DA. Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. J Nucl Med. 2004;45:129–37.PubMed

12.

Confino H, Hochman I, Efrati M, Schmidt M, Umansky V, Kelson I, et al. Tumor ablation by intratumoral Ra-224-loaded wires induces anti-tumor immunity against experimental metastatic tumors. Cancer Immunol Immunother. 2015;64:191–9.CrossRefPubMed

13.

De Kruijff RM, Wolterbeek HT, Denkova AG. A critical review of alpha radionuclide therapy-how to deal with recoiling daughters? Pharmaceuticals. 2015;8:321–36.CrossRefPubMedPubMedCentral

14.

Li T, Ao ECI, Lambert B, Brans B, Vandenberghe S, Mok GSP. Quantitative imaging for targeted radionuclide therapy dosimetry - technical review. Theranostics. 2017;7:4551–65.CrossRefPubMedPubMedCentral

15.

Rong X, Ghaly M, Frey EC. Optimization of energy window for 90Y bremsstrahlung SPECT imaging for detection tasks using the ideal observer with model-mismatch. Med Phys. 2013;40:062502.CrossRefPubMedPubMedCentral

16.

Minarik D, Sjogreen-Gleisner K, Linden O, Wingardh K, Tennvall J, Strand SE, et al. 90Y bremsstrahlung imaging for absorbed-dose assessment in high-dose radioimmunotherapy. J Nucl Med. 2010;51:1974–8.CrossRefPubMed

17.

Minarik D, Ljungberg M, Segars P, Gleisner KS. Evaluation of quantitative planar 90Y bremsstrahlung whole-body imaging. Phys Med Biol. 2009;54:5873–83.CrossRefPubMed

18.

Rong X, Frey EC. A collimator optimization method for quantitative imaging: application to Y-90 bremsstrahlung SPECT. Med Phys. 2013;40:082504.CrossRefPubMedPubMedCentral

19.

Rong X, Du Y, Frey EC. A method for energy window optimization for quantitative tasks that includes the effects of model-mismatch on bias: application to Y-90 bremsstrahlung SPECT imaging. Phys Med Biol. 2012;57:3711–25.CrossRefPubMedPubMedCentral

20.

Siegel JA, Zeiger LS, Order SE, Wallner PE. Quantitative bremsstrahlung single photon emission computed tomographic imaging: use for volume, activity, and absorbed dose calculations. Int J Radiat Oncol Biol Phys. 1995;31:953–8.CrossRefPubMed

21.

Shen S, DeNardo GL, DeNardo SJ. Quantitative bremsstrahlung imaging of yttrium-90 using a Wiener filter. Med Phys. 1994;21:1409–17.CrossRefPubMed

22.

Siegel JA. Quantitative bremsstrahlung SPECT imaging: attenuation-corrected activity determination. J Nucl Med. 1994;35:1213–6.PubMed

23.

Lim H, Fessler JA, Wilderman SJ, Brooks AF, Dewaraja YK. Y-90 SPECT ML image reconstruction with a new model for tissue-dependent bremsstrahlung production using CT information: a proof-of-concept study. Phys Med Biol. 2018;63:115001.CrossRefPubMedPubMedCentral

24.

Muller C, Vermeulen C, Koster U, Johnston K, Turler A, Schibli R, et al. Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics. EJNMMI Radiopharm Chem. 2017;1:5.CrossRefPubMed

25.

Ackerman NL, Graves EE. The potential for Cerenkov luminescence imaging of alpha-emitting radionuclides. Phys Med Biol. 2012;57:771–83.CrossRefPubMedPubMedCentral

26.

Wood V, Ackerman NL. Cherenkov light production from the alpha-emitting decay chains of (223)Ra, (212)Pb, and (149)Tb for Cherenkov luminescence imaging. Appl Radiat Isot. 2016;118:354–60.CrossRefPubMed

27.

Boschi F, De Sanctis F, Spinelli AE. Optical emission of (223) radium: in vitro and in vivo preclinical applications. J Biophotonics. 2018;11:e201700209.CrossRefPubMed

28.

Pandya DN, Hantgan R, Budzevich MM, Kock ND, Morse DL, Batista I, et al. Preliminary therapy evaluation of (225)Ac-DOTA-c(RGDyK) demonstrates that Cerenkov radiation derived from (225)Ac daughter decay can be detected by optical imaging for in vivo tumor visualization. Theranostics. 2016;6:698–709.CrossRefPubMedPubMedCentral

29.

Cistaro A, Quartuccio N, Caobelli F, Piccardo A, Paratore R, Coppolino P, et al. 124I-MIBG: a new promising positron-emitting radiopharmaceutical for the evaluation of neuroblastoma. Nucl Med Rev Cent East Eur. 2015;18:102–6.CrossRefPubMed

30.

Moroz MA, Serganova I, Zanzonico P, Ageyeva L, Beresten T, Dyomina E, et al. Imaging hNET reporter gene expression with 124I-MIBG. J Nucl Med. 2007;48:827–36.CrossRefPubMed

31.

Ott RJ, Tait D, Flower MA, Babich JW, Lambrecht RM. Treatment planning for 131I-mIBG radiotherapy of neural crest tumours using 124I-mIBG positron emission tomography. Br J Radiol. 1992;65:787–91.CrossRefPubMed

32.

Seo Y, Gustafson WC, Dannoon SF, Nekritz EA, Lee CL, Murphy ST, et al. Tumor dosimetry using [124I]m-iodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model. Mol Imaging Biol. 2012;14:735–42.CrossRefPubMedPubMedCentral

33.

Lee CL, Wahnishe H, Sayre GA, Cho HM, Kim HJ, Hernandez-Pampaloni M, et al. Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET. Med Phys. 2010;37:4861–7.CrossRefPubMedPubMedCentral

34.

Vaidyanathan G, Affleck DJ, Alston KL, Zhao XG, Hens M, Hunter DH, et al. A kit method for the high level synthesis of [211At]MABG. Bioorg Med Chem. 2007;15:3430–6.CrossRefPubMedPubMedCentral

Titel: Quantitative Imaging of Alpha-Emitting Therapeutic Radiopharmaceuticals
verfasst von: Youngho Seo
Publikationsdatum: 18.02.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Nuclear Medicine and Molecular Imaging / Ausgabe 3/2019
Print ISSN: 1869-3474
Elektronische ISSN: 1869-3482
DOI: https://doi.org/10.1007/s13139-019-00589-8

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Quantitative Imaging of Alpha-Emitting Therapeutic Radiopharmaceuticals

Abstract

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

Use of Molecular Imaging in Clinical Drug Development: a Systematic Review

Clinical Applications of Technetium-99m Quantitative Single-Photon Emission Computed Tomography/Computed Tomography

Perspectives for Concepts of Individualized Radionuclide Therapy, Molecular Radiotherapy, and Theranostic Approaches

Eruption of Metastatic Paraganglioma After Successful Therapy with 177Lu/90Y-DOTATOC and 177Lu-DOTATATE

Clinical Personal Connectomics Using Hybrid PET/MRI

Perspectives in Radiomics for Personalized Medicine and Theranostics